10212T

9/12

◉抽出文献（2）その他の免疫療法 10） Jeung HC, Moon YW, Rha SY, et al. Phase III trial of adjuvant 5‒fluorouracil and adriamycin versus 5‒fluoro-uracil, adriamycin, and polyadenylic‒polyuridylic acid（poly A：U）for locally advanced gastric cancer after curative surgery：final results of 15‒year follow‒up. Ann Oncol. 2008；19（3）：520‒6.がん免疫療法のがん種別エビデンス3胃癌121 2） Kang YK, Chen LT, Ryu MH, et al. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2‒negative, untreated, unresectable advanced or recurrent gastric or gastro‒oesophageal junction cancer（ATTRACTION‒4）：a randomised, multicentre, double‒blind, placebo‒controlled, phase 3 trial. Lancet Oncol. 2022；23（2）：234‒47. 3） Shitara K, Van Cutsem E, Bang YJ, et al. Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Che-motherapy vs Chemotherapy Alone for Patients With First‒line, Advanced Gastric Cancer：The KEY-NOTE‒062 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2020；6（10）：1571‒80. 4） Moehler M, Dvorkin M, Boku N, et al. Phase III Trial of Avelumab Maintenance After First‒Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients With Gastric Cancers：Results From JAV-ELIN Gastric 100. J Clin Oncol. 2021；39（9）：966‒77. 5） Bang YJ, Cho JY, Kim YH, et al. Efficacy of Sequential Ipilimumab Monotherapy versus Best Supportive Care for Unresectable Locally Advanced／Metastatic Gastric or Gastroesophageal Iunction Cancer. Clin Cancer Res. 2017；23（19）：5671‒8. 6） Shitara K, Özgüroğlu M, Bang YJ, et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro‒oesophageal junction cancer（KEYNOTE‒061）：a randomised, open‒label, controlled, phase 3 trial. Lancet. 2018；392（10142）：123‒33. 7） Pietrantonio F, Randon G, Di Bartolomeo M, et al. Predictive role of microsatellite instability for PD‒1 block-ade in patients with advanced gastric cancer：a meta‒analysis of randomized clinical trials. ESMO Open. 2021；6（1）：100036. 8） Kang YK, Boku N, Satoh T, et al. Nivolumab in patients with advanced gastric or gastro‒oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens（ONO‒4538‒12, ATTRACTION‒2）：a randomised, double‒blind, placebo‒controlled, phase 3 trial. Lancet. 2017；390（10111）：2461‒71. 9） Bang YJ, Yañez Ruiz E, Van Cutsem E, et al. Phase III, randomised trial of avelumab versus physicianʼs choice of chemotherapy as third‒line treatment of patients with advanced gastric or gastro‒oesophageal junction cancer：primary analysis of JAVELIN Gastric 300. Ann Oncol. 2018；29（10）：2052‒60. 11） Popiela T, Kulig J, Czupryna A, et al. Efficiency of adjuvant immunochemotherapy following curative resection in patients with locally advanced gastric cancer. Gastric Cancer. 2004；7（4）：240‒5.進行期・一次治療ⒶHER2陰性未治療切除不能進行・転移性胃癌・食道胃接合部癌・食道癌（腺癌）を対象として，標準化学療法（CapeOX療法またはFOLFOX療法）に対するニボルマブの上乗せ効果あるいはニボルマブ＋イピリムマブの優越性を検証する比較第Ⅲ相試験（CheckMate 649試験）が行◉抽出文献（1）免疫チェックポイント阻害薬 1） Janjigian YY, Shitara K, Moehler M, et al. First‒line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro‒oesophageal junction, and oesophageal adenocarcinoma（CheckMate 649）：a ran-domised, open‒label, phase 3 trial. Lancet. 2021；398（10294）：27‒40.◉エビデンスの解説（1）免疫チェックポイント阻害薬サーチ4報），その他の免疫療法2報であった。・ ハンドサーチにて，ランダム化比較試験のサブグループ解析報告1報を採用した。Ⅲ